Literature DB >> 27224987

Safety and Efficacy of Percutaneous Biliary Covered Stent Placement in Patients with Malignant Biliary Hilar Obstruction; Correlation with Liver Function.

Hyeran Hyun1, Sun Young Choi2, Kyung Ah Kim3, Soo Bin Ko4.   

Abstract

PURPOSE: To estimate the safety and efficacy of percutaneous ePTFE-covered biliary stent placement and the relationship between underlying liver function and stent patency in patients with malignant hilar obstruction.
MATERIALS AND METHODS: From March 2012 to June 2015, 41 patients [22 females, 19 males; mean age 69.8 (range 34-94) years] with malignant biliary obstruction underwent percutaneous biliary stent placement (31 patients with unilateral, 10 patients with bilateral side-by-side). Cumulative patient survival and stent patency rate curves were derived using the Kaplan-Meier method. A Cox model was used to explore the relationship between liver function and patient survival, and also biliary stent patency. Pearson correlation coefficient was used to analyze the relationship between patient survival and stent patency.
RESULTS: Technical success rate was 100 % and clinical success rate was 95 %. During follow-up, four complications occurred (two bilomas and two cases of acute cholecystitis) and were treated successfully with percutaneous drainage. No other complication occurred. Mean serum bilirubin level was 11.34 ± 7.35 mg/dL before drainage and 5.00 ± 4.83 mg/dL 2 weeks after stent placement. The median patent survival duration was 147 days (95 % CI, 69.6-224.4 days). The median stent patency duration was 101 days (95 % CI, 70.0-132.0 days). The cumulative stent patency rates at 1, 3, 6, and 12 months were 97, 57.6, 30.3, and 17.0 %, respectively. Child-Pugh score was correlated significantly with patient survival (P = 0.011) and stent patency (P = 0.007). MELD score was correlated significantly with stent patency (P = 0.044). There was a correlation between patient survival and stent patency (r = 0.778, P < 0.001).
CONCLUSION: Percutaneous placement of ePTFE-covered biliary stent was a safe and an effective method for malignant biliary obstruction. Underlying liver function seemed to be one of the important factors affecting patient survival and stent patency, and stent patency showed statistically significant correlation with patient survival.

Entities:  

Keywords:  Biliary stent placement; Covered stent; Malignant hilar obstruction

Mesh:

Year:  2016        PMID: 27224987     DOI: 10.1007/s00270-016-1375-5

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

1.  Safety and efficacy of percutaneous transhepatic-endoscopic rendezvous procedure in a single session.

Authors:  Cyril Chivot; Clara Yzet; Roger Bouzerar; Franck Brazier; Sami Hakim; Jean Philippe Le Mouel; Eric Nguyen-Khac; Richard Delcenserie; Thierry Yzet
Journal:  Surg Endosc       Date:  2020-07-24       Impact factor: 4.584

Review 2.  Palliative Percutaneous Biliary Interventions in Malignant High Bile Duct Obstruction.

Authors:  Amy R Deipolyi; Anne M Covey
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

3.  No evidence of improved efficacy of covered stents over uncovered stents in percutaneous palliation of malignant hilar biliary obstruction: results of a prospective randomized trial.

Authors:  Elisabeth Dhondt; Peter Vanlangenhove; Karen Geboes; Lisbeth Vandenabeele; Lien Van Cauwenberghe; Luc Defreyne
Journal:  Eur Radiol       Date:  2019-08-05       Impact factor: 5.315

4.  Albumin-Bilirubin Grade as a Novel Predictor of Survival in Advanced Extrahepatic Cholangiocarcinoma.

Authors:  Yong Wang; Qing Pang; Hao Jin; Lei Zhou; Xiaosi Hu; Zhen Qian; Zhongran Man; Song Yang; Huichun Liu
Journal:  Gastroenterol Res Pract       Date:  2018-12-02       Impact factor: 2.260

5.  Percutaneous Metallic Stent Placement for Palliative Management of Malignant Biliary Hilar Obstruction.

Authors:  Dong Jae Shim; Dong Il Gwon; Kichang Han; Yook Kim; Gi-Young Ko; Ji Hoon Shin; Heung Kyu Ko; Jin Hyoung Kim; Jong Woo Kim; Hyun-Ki Yoon; Kyu-Bo Sung
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.